BioSpace News Archive

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics, and Servier, a global pharmaceutical group, announced today that they have entered into a collaboration agreement that will use Aqemia’s technology to accelerate the discovery of small molecule therapeutic drug candidates on an undisclosed target in immuno-oncology.

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) has approved Injectafer for pediatric patients (who are 1 year of age or older) with iron deficiency anemia (IDA) who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.

Viome Life Sciences (VLS) announces the publication of a clinical study performed with leading researchers and clinicians for early detection of life-threatening cancer or its precursors, and the launch of its Grants Program to encourage collaborative research.

EVERSANA, the pioneer of next generation services to the global life sciences industry, today announced an agreement with Janssen Research & Development, LLC (Janssen) to transform clinical data into the much-needed evolution of chronic disease care through real-word data (RWD), data science analysis and regulatory-grade studies.

Hospital for Special Surgery President and CEO Louis A. Shapiro and Surgeon-in Chief and Medical Director Bryan T. Kelly, MD, announced the appointment of Michael P. Ast, MD, hip and knee replacement surgeon and assistant professor of orthopaedic surgery, as the new Vice-Chair of the HSS Innovation Institute and Chief Medical Innovation Officer.

CEA-Leti, a CEA microelectronics research institute, will introduce a smart, integrated multi-sensor system for knee implants at CES 2022 that can help surgeons more accurately position the implant, dramatically reduce risk of follow-up surgery, and enhance rehabilitation.

Collaborative research program will assess potential for Satellos drug candidates to treat rare dystrophic disease indications.

Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued advice on the use of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), stating that PAXLOVID can be used to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.

Immunolight LLC, announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center.

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, announced the appointment of Richard Blackburn to its advisory board.